Demodex Blepharitis

Richard L. Lindstrom, MD, discusses the phase 2a Mars study results of TP-03 for the treatment of Demodex blepharitis, presented at the virtual Association for Research in Vision and Ophthalmology meeting.

Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing that will be used to initiate a phase 2b/3 trial of topical ophthalmic TP-03 for the treatment of Demodex blepharitis.

No matter what patients desire — success in contact lenses, refractive freedom with LASIK or superior visual outcomes after cataract surgery — the health of the cornea is paramount.